$1.6bn Bharat Serums Buy Gives Mankind Dominance In Women's Health, R&D Engine
PE Firm Advent Exits At 22-23x FY25 EBITDA
With an eye-catching $1.6bn deal, Mankind has acquired Bharat Serums and Vaccines to add a high-barrier, specialty business, a credible biologics R&D engine and a complementary portfolio of women’s fertility and health treatments while PE firm Advent finds a profitable exit. What’s next?
